Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Latest shares articles
Trading the Nasdaq 100 as Tariffs Take Effect
Not far off recovering from last Thursday’s losses buoyed by big gains from a few of Big Tech, and in sentiment still a story of majority buy bias.
6 hours ago
Capital.com donates €50,000 to the Cyprus Red Cross Society to support wildfire relief efforts
Capital.com donates €50,000 to the Cyprus Red Cross Society to aid families affected by wildfires, reinforcing its commitment to community support.
09:49, 5 August 2025
Trading the Dow 30 after the disappointing Non-Farm Payrolls
Technical overview shifts in the key index following the pullback late last week made worse by a deteriorating labor market, while CoT speculators shift to net sell for the first time in months.
07:55, 4 August 2025
Forex CFDs: Understanding currency forwards vs spot markets
Spot or forward? These two forex markets behave differently, and now you can trade both with us as forex CFDs. Here’s how they work, and what sets them apart.
14:48, 31 July 2025
Ratings and Reviews
Ratings and Reviews
